{"content":"<li class=\"n-box-item date-title\" data-end=\"1505275199\" data-start=\"1505188800\" data-txt=\"Monday, December 23, 2019\">Tuesday, September 12, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3295015\" data-ts=\"1505259987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295015-boot-barn-buys-texas-based-woods-boots\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn buys Texas-based Wood&#39;s Boots</a></h4><ul>   <li>Boot Barn (<a href=\"http://seekingalpha.com/symbol/BOOT\" target=\"_blank\">BOOT</a> <font color='green'>+2.2%</font>) says it's wrapped a transaction to <a href=\"https://seekingalpha.com/pr/16938840-boot-barn-holdings-inc-acquires-four-store-boot-chain-texas-provides-hurricane-impact-update\" target=\"_blank\">acquire Wood's Boots</a>, a Texas retailer with a four-store operation.</li>    <li>Full terms were undisclosed but the deal was done with cash on hand, and involved buying inventory, setting new leases and offering employment at all four locations.</li>    <li>Wood's Boots is based in Midland and Odessa, Texas.</li>    <li>Boot Barn also says that while 20 Houston-area stores temporarily closed due to Hurricane Harvey, all but two of the stores reopened within a week. The two other stores experienced significant flooding and will be closed during repairs. Employees are safe and the company doesn't believe there were significant storm-related losses.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295015\" data-linked=\"Boot Barn buys Texas-based Wood&#39;s Boots\" data-tweet=\"$BOOT - Boot Barn buys Texas-based Wood&#39;s Boots https://seekingalpha.com/news/3295015-boot-barn-buys-texas-based-woods-boots?source=tweet\" data-url=\"https://seekingalpha.com/news/3295015-boot-barn-buys-texas-based-woods-boots\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295011\" data-ts=\"1505255583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295011-seadrill-files-for-bankruptcy-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill files for bankruptcy (updated)</a></h4><ul>   <li>As it had signaled last month, Seadrill (<a href=\"http://seekingalpha.com/symbol/SDRL\" target=\"_blank\">SDRL</a> <font color='green'>+17.6%</font>) has filed for bankruptcy in Texas.</li>    <li>The deepwater firm had said a Chapter 11 filing was <a href=\"https://seekingalpha.com/news/3291434-seadrill-slides-prepares-chap-11\" target=\"_blank\">likely by today</a> as it worked to raise $1B in new capital and get a five-year extension for its bank facilities.</li><li><strong>Updated:</strong> Seadrill says it's reached a restructuring agreement with 97% of secured lenders, about 40% of its bondholders and a consortium of investors led by top shareholder Hemen Holding. That will bring $1.06B in new capital ($860M in secured notes, $200M in equity) along with deferrals of $5.7B in secured credit facilities by about five years.</li><li><a href=\"http://www.nasdaq.com/press-release/sdrl--seadrill-announces-comprehensive-restructuring-plan-to-be-implemented-with-prearranged-20170912-01450\" target=\"_blank\">Company press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3295011\" data-linked=\"Seadrill files for bankruptcy (updated)\" data-tweet=\"$SDRL - Seadrill files for bankruptcy (updated) https://seekingalpha.com/news/3295011-seadrill-files-for-bankruptcy-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3295011-seadrill-files-for-bankruptcy-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>209&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295004\" data-ts=\"1505252249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295004-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='green'>+8.8%</font>. <a href='https://seekingalpha.com/symbol/BKE' title='The Buckle, Inc.'>BKE</a> <font color='green'>+3.6%</font>. EXXI <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+2.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/AMRK' title='A-Mark Precious Metals, Inc.'>AMRK</a> <font color='red'>-14.9%</font>. SWNC <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='red'>-3.1%</font>. <a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='red'>-3.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295004\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$JWN $BKE $EGC - After Hours Gainers / Losers https://seekingalpha.com/news/3295004-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3295004-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294998\" data-ts=\"1505249726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294998-crude-oil-stocks-jumped-6_18m-barrels-last-week-api\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil stocks jumped 6.18M barrels last week - API</a></h4><ul><li>If the EIA confirms something close to that number tomorrow morning, it would be the largest build in oil stocks since March. Refinery shutdowns due to Hurricane Harvey no doubt affected the print. Trade expectations were for a rise of 4.91M barrels.</li><li>Oil's little-changed after hours at $48.34 per barrel.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/UHN' title='The United States Diesel-Heating Oil ETF, LP'>UHN</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294998\" data-linked=\"Crude oil stocks jumped 6.18M barrels last week - API\" data-tweet=\"$USO $OIL $UWT - Crude oil stocks jumped 6.18M barrels last week - API https://seekingalpha.com/news/3294998-crude-oil-stocks-jumped-6_18m-barrels-last-week-api?source=tweet\" data-url=\"https://seekingalpha.com/news/3294998-crude-oil-stocks-jumped-6_18m-barrels-last-week-api\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294993\" data-ts=\"1505249577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNC\" target=\"_blank\">CNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294993-centene-to-acquire-fidelis-care-for-3_75b-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centene to acquire Fidelis Care for $3.75B; shares up 1% after hours</a></h4><ul><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) inks an <a href=\"https://seekingalpha.com/pr/16938787-centene-corporation-enter-new-york-transaction-fidelis-care\" target=\"_blank\">agreement </a>with Fidelis Care to acquire substantially all of its assets for $3.75B, subject to adjustments.</li><li>Non-profit Fidelis is a leader in government healthcare plans, serving over 1.6M members. It generated $4.8B in revenues for the six-month period ending June 20.</li><li>The transaction will give Centene a leadership position in New York, adding to its leading presence in California, Florida and Texas, the top four managed care states.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294993\" data-linked=\"Centene to acquire Fidelis Care for $3.75B; shares up 1% after hours\" data-tweet=\"$CNC - Centene to acquire Fidelis Care for $3.75B; shares up 1% after hours https://seekingalpha.com/news/3294993-centene-to-acquire-fidelis-care-for-3_75b-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3294993-centene-to-acquire-fidelis-care-for-3_75b-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294977\" data-ts=\"1505248513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KKR\" target=\"_blank\">KKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294977-nordstromplus-8_2-on-report-nearing-go-private-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom +8.2% on report it&#39;s nearing go-private deal</a></h4><ul>   <li>The Nordstrom family (<a href=\"http://seekingalpha.com/symbol/JWN\" target=\"_blank\">JWN</a> <font color='green'>+0.7%</font>) is closing in on a <a href=\"https://www.cnbc.com/2017/09/12/nordstrom-family-nears-deal-with-leonard-green-for-nordstrom-buyout.htm\" target=\"_blank\">deal to take the department store private</a> with private-equity firm Leonard Green, CNBC reports.</li>    <li>Shares have <font color='green'>jumped 8.2%</font> after hours.</li>    <li>The family said in June it was looking for a go-private deal.</li>    <li>Leonard Green would help with about $1B in equity to fund the deal. The family group is discussing $7B-$8B in debt to finance it.</li><li>It's not a final deal yet, CNBC says, and so other parties (Nordstrom was also talking with <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> and Apollo (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>)) might try to intercede.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294977\" data-linked=\"Nordstrom +8.2% on report it&#39;s nearing go-private deal\" data-tweet=\"$KKR $KKR $APO - Nordstrom +8.2% on report it&#39;s nearing go-private deal https://seekingalpha.com/news/3294977-nordstromplus-8_2-on-report-nearing-go-private-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3294977-nordstromplus-8_2-on-report-nearing-go-private-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294971\" data-ts=\"1505247920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZFGN\" target=\"_blank\">ZFGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294971-zafgen-launches-mid-stage-study-of-zgnminus-1061-in-type-2-diabetics-shares-ahead-5-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zafgen launches mid-stage study of ZGN-1061 in type 2 diabetics; shares ahead 5% after hours</a></h4><ul><li>Zafgen (NASDAQ:<a href='https://seekingalpha.com/symbol/ZFGN' title='Zafgen, Inc.'>ZFGN</a>) <a href=\"https://seekingalpha.com/pr/16938704-zafgen-initiates-phase-2-clinical-trial-zgnminus-1061-patients-type-2-diabetes\" target=\"_blank\">initiates </a>a Phase 2 clinical trial assessing the ability of ZGN-1061 to control blood sugar levels in patients with type 2 diabetes. The 120-subject randomized placebo-controlled study will evaluate three doses of ZGN-1061 for 12 weeks in sites in Australia and New Zealand.</li><li>Interim data should be available in H1 2018.</li><li>ZGN-1061 is a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor designed to improve glycemic control while helping to restore balance to fat metabolism. A fumagillin is an antimicrobial agent. MetAP2 is an enzyme that plays a key role tissue repair, angiogenesis and protein degradation and has demonstrated an ability to induce weight loss.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;after hours but only on 118 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294971\" data-linked=\"Zafgen launches mid-stage study of ZGN-1061 in type 2 diabetics; shares ahead 5% after hours\" data-tweet=\"$ZFGN - Zafgen launches mid-stage study of ZGN-1061 in type 2 diabetics; shares ahead 5% after hours https://seekingalpha.com/news/3294971-zafgen-launches-mid-stage-study-of-zgnminus-1061-in-type-2-diabetics-shares-ahead-5-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3294971-zafgen-launches-mid-stage-study-of-zgnminus-1061-in-type-2-diabetics-shares-ahead-5-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294960\" data-ts=\"1505246831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294960-celldex-medical-chief-bids-adieu-shares-off-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celldex medical chief bids adieu; shares off 3% after hours</a></h4><ul><li>Celldex Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a>) EVP and Chief Medical Officer Thomas Davis, M.D. will <a href=\"https://seekingalpha.com/pr/16938685-celldex-announces-departure-chief-medical-officer\" target=\"_blank\">resign </a>effective September 29 for undisclosed reasons. No word is given on a successor.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294960\" data-linked=\"Celldex medical chief bids adieu; shares off 3% after hours\" data-tweet=\"$CLDX - Celldex medical chief bids adieu; shares off 3% after hours https://seekingalpha.com/news/3294960-celldex-medical-chief-bids-adieu-shares-off-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3294960-celldex-medical-chief-bids-adieu-shares-off-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294951\" data-ts=\"1505245609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGO\" target=\"_blank\">PRGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294951-starboard-likes-perrigo-undervalued-despite-strong-otc-business-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starboard likes Perrigo, undervalued despite strong OTC business; shares up 4%</a></h4><ul><li>Jeffrey Smith, CEO and CIO of hedge fund Starboard Value says generic drug maker Perrigo (<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='green'>+4.4%</font>) is his \"<a href=\"http://www.institutionalinvestor.com/article/3750390/investors-delivering-alpha/starboards-jeffrey-smith-calls-perrigo-his-firms-best-idea.html?utm_source=Twitter&amp;utm_medium=Organic%20Social&amp;utm_term=Editorial&amp;utm_campaign=Institutional%20Investor#/.Wbg2pMiGNhF\" target=\"_blank\">best idea</a>.\"</li><li>He cites the \"consistent and defensible\" growth of its U.S. OTC business and progress in its international consumer segment. Generics have been facing downward price pressures for some time, but he adds that the company is in the midst of a strategic review that may entail an outright sale, partnership or spinoff.</li><li>Shares have rallied almost 40% since bottoming at $63.68 on August 9.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294951\" data-linked=\"Starboard likes Perrigo, undervalued despite strong OTC business; shares up 4%\" data-tweet=\"$PRGO - Starboard likes Perrigo, undervalued despite strong OTC business; shares up 4% https://seekingalpha.com/news/3294951-starboard-likes-perrigo-undervalued-despite-strong-otc-business-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3294951-starboard-likes-perrigo-undervalued-despite-strong-otc-business-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294950\" data-ts=\"1505245237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294950-massachusetts-set-to-sue-equifax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Massachusetts set to sue Equifax</a></h4><ul><li>The state's Attorney General's Office sent a letter to Equifax (NYSE:<a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a>) informing the company of its intent to sue in five days. The company is also dealing with a probe by the New York AG, and U.S. congressional committees are getting into the act as well.</li><li>Shares are<font color='green'> higher by 1.4%</font>&nbsp;today after a&nbsp;<font color='red'>20% two-session slide</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294950\" data-linked=\"Massachusetts set to sue Equifax\" data-tweet=\"$EFX - Massachusetts set to sue Equifax https://seekingalpha.com/news/3294950-massachusetts-set-to-sue-equifax?source=tweet\" data-url=\"https://seekingalpha.com/news/3294950-massachusetts-set-to-sue-equifax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294949\" data-ts=\"1505245163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294949-energous-plunges-after-apple-announces-different-path-to-wireless-charging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous plunges after Apple announces different path to wireless charging</a></h4><ul><li>        Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) shares&nbsp;<font color='red'>plunge 10.7%</font>&nbsp;after the Apple launch event revealed that the tech giant was using the Qi standard for its new wirelessly charging devices.</li><li>Energous creates teh WattUp wire-free charging technology and had a couple of years ago&nbsp;<a href=\"https://www.cnbc.com/2017/09/12/energous-stock-drops-after-apple-announces-iphone-8-wireless-charging.html\" target=\"_blank\">hinted</a>&nbsp;at a big name tech partner that many at the time thought was Apple.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294897-apple-iphone-event-2017-live-updates\" target=\"_blank\">Apple iPhone Event 2017: Live updates</a> (Sept. 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294940-optical-stocks-moving-apple-covers-augmented-reality\" target=\"_blank\">Optical stocks moving as Apple covers augmented reality</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294949\" data-linked=\"Energous plunges after Apple announces different path to wireless charging\" data-tweet=\"$WATT - Energous plunges after Apple announces different path to wireless charging https://seekingalpha.com/news/3294949-energous-plunges-after-apple-announces-different-path-to-wireless-charging?source=tweet\" data-url=\"https://seekingalpha.com/news/3294949-energous-plunges-after-apple-announces-different-path-to-wireless-charging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294947\" data-ts=\"1505244454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DUK\" target=\"_blank\">DUK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294947-duke-energy-down-1-reports-significant-transmission-damage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duke Energy down more than 1%, reports &#39;significant&#39; transmission damage</a></h4><ul><li>Damage includes transmission towers, numerous substations, and trees on power lines, says the company in an email to Bloomberg. About 1M of Duke's (<a href='https://seekingalpha.com/symbol/DUK' title='Duke Energy Corporation'>DUK</a> <font color='red'>-1.1%</font>) 1.8M Florida customers are without power.</li><li>Repairs are underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294947\" data-linked=\"Duke Energy down more than 1%, reports &#39;significant&#39; transmission damage\" data-tweet=\"$DUK - Duke Energy down more than 1%, reports &#39;significant&#39; transmission damage https://seekingalpha.com/news/3294947-duke-energy-down-1-reports-significant-transmission-damage?source=tweet\" data-url=\"https://seekingalpha.com/news/3294947-duke-energy-down-1-reports-significant-transmission-damage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294944\" data-ts=\"1505243435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLR\" target=\"_blank\">CLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294944-continental-resources-loses-gains-on-chanos-remarks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Continental Resources loses gains on Chanos remarks</a></h4><ul><li>Addressing the Delivering Alpha conference, Jim Chanos is taking aim at the fracking industry.</li><li>Continental Resources (NYSE:<a href='https://seekingalpha.com/symbol/CLR' title='Continental Resources, Inc.'>CLR</a>), he says, may be struggling to make its interest payments. In fact, he says, the company struggles to generate free cash flow at any time.</li><li>Shares have&nbsp;<font color='red'>dipped about 3%</font>&nbsp;since Chanos' remarks, now flat on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294944\" data-linked=\"Continental Resources loses gains on Chanos remarks\" data-tweet=\"$CLR - Continental Resources loses gains on Chanos remarks https://seekingalpha.com/news/3294944-continental-resources-loses-gains-on-chanos-remarks?source=tweet\" data-url=\"https://seekingalpha.com/news/3294944-continental-resources-loses-gains-on-chanos-remarks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294941\" data-ts=\"1505242509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294941-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INOV' title='Inovalon'>INOV</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-24%</font>. COGT <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks, Inc'>LOV</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294941\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$INOV $RFIL $VERI - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3294941-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294941-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294940\" data-ts=\"1505242453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294940-optical-stocks-moving-apple-covers-augmented-reality\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optical stocks moving as Apple covers augmented reality</a></h4><ul>   <li>With Apple getting to the augmented reality features of its new iPhones in <a href=\"https://seekingalpha.com/news/3294897-apple-iphone-event-2017-live-updates\" target=\"_blank\">today's launch event</a>, optical-equipment stocks are on the move with some choppy trading.</li>    <li>After a flat middle of today's session, Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) is back up, <font color='green'>+2.6%</font> on the day. II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) is <font color='green'>up 1.5%</font>.</li>    <li>Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>), meanwhile, spiked to a high of $60 (<font color='green'>up 2.6%</font>) before falling back to $57.55 (<font color='red'>down 1.6%</font> on the day.)</li>    <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) is holding <font color='green'>2% gains</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294940\" data-linked=\"Optical stocks moving as Apple covers augmented reality\" data-tweet=\"$FNSR $FNSR $IIVI - Optical stocks moving as Apple covers augmented reality https://seekingalpha.com/news/3294940-optical-stocks-moving-apple-covers-augmented-reality?source=tweet\" data-url=\"https://seekingalpha.com/news/3294940-optical-stocks-moving-apple-covers-augmented-reality\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294937\" data-ts=\"1505241792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTCS\" target=\"_blank\">BTCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294937-dimon-bitcoin-fraud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dimon: Bitcoin a fraud</a></h4><ul><li>Addressing the Barclays conference, JPMorgan CEO Jamie Dimon says he would fire any trader for stupidity for trading bitcoin. The craze, he says, is worse than tulip bulbs.</li><li>Bitcoin is&nbsp;<font color='red'>lower by 1.9%&nbsp;</font>on the session.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294937\" data-linked=\"Dimon: Bitcoin a fraud\" data-tweet=\"$BTCS $COIN $BTCS - Dimon: Bitcoin a fraud https://seekingalpha.com/news/3294937-dimon-bitcoin-fraud?source=tweet\" data-url=\"https://seekingalpha.com/news/3294937-dimon-bitcoin-fraud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>264&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294935\" data-ts=\"1505240153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERIC\" target=\"_blank\">ERIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294935-ericsson-gives-heuveldop-helm-of-north-american-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ericsson gives Heuveldop helm of North American market</a></h4><ul>   <li>Ericsson (<a href=\"http://seekingalpha.com/symbol/ERIC\" target=\"_blank\">ERIC</a> <font color='green'>+1.7%</font>) has made a <a href=\"https://seekingalpha.com/pr/16938158-ericsson-announces-changes-executive-team\" target=\"_blank\">change in its executive team</a>, making Niklas Heuveldop its permanent Head of Market Area North America.</li>    <li>Heuveldop has been acting in that role since May, and already holds the title of chief strategy officer and head of Technology &amp; Emerging Business.</li>    <li>He'll become acting chief in the former roles as he permanently takes on the North American organization -- some 11,500 employees serving customers in the U.S. and Canada.</li>    <li>He'll also maintain his role as senior VP. The changes are effective today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294935\" data-linked=\"Ericsson gives Heuveldop helm of North American market\" data-tweet=\"$ERIC - Ericsson gives Heuveldop helm of North American market https://seekingalpha.com/news/3294935-ericsson-gives-heuveldop-helm-of-north-american-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3294935-ericsson-gives-heuveldop-helm-of-north-american-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294933\" data-ts=\"1505239322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294933-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294933\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$SAEX $CDXC $FMSA - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3294933-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294933-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294923\" data-ts=\"1505236853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAKE\" target=\"_blank\">CAKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294923-restaurant-stocks-recover-from-pre-irma-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restaurant stocks recover from pre-Irma slide</a></h4><ul><li>Restaurant stocks with a high mix of locations in Florida are showing some gains as the statewide impact from Hurricane Irma becomes clearer.</li><li>Cheesecake Factory (<a href='https://seekingalpha.com/symbol/CAKE' title='The Cheesecake Factory Incorporated'>CAKE</a> <font color='green'>+2.8%</font>), Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='green'>+4.4%</font>), Ruth's Hospitality Group (<a href='https://seekingalpha.com/symbol/RUTH' title='Ruth&#39;s Hospitality Group, Inc.'>RUTH</a> <font color='green'>+4.2%</font>), Brinker International (<a href='https://seekingalpha.com/symbol/EAT' title='Brinker International, Inc.'>EAT</a> <font color='green'>+4.2%</font>), Red Robin Gourmet Burgers (<a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a> <font color='green'>+2.9%</font>), Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='green'>+2.5%</font>) and Darden Restaurants (<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a> <font color='green'>+1.7%</font>) are among the restaurant names recovering from last week's slide.</li><li>Restaurant ETF: <a href='https://seekingalpha.com/symbol/MENU' title='USCF Restaurant Leaders ETF'>MENU</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294923\" data-linked=\"Restaurant stocks recover from pre-Irma slide\" data-tweet=\"$CAKE $CAKE $BWLD - Restaurant stocks recover from pre-Irma slide https://seekingalpha.com/news/3294923-restaurant-stocks-recover-from-pre-irma-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3294923-restaurant-stocks-recover-from-pre-irma-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294919\" data-ts=\"1505235864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESRX\" target=\"_blank\">ESRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294919-express-scripts-slips-on-chanos-continued-bearish-thesis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Express Scripts slips on Chanos&#39; continued bearish thesis</a></h4><ul><li>Pharmacy benefits manager Express Scripts (<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='red'>-1.4%</font>) is under pressure in apparent reaction to comments from celebrity investor Jim Chanos on CNBC. He has had a negative view on the company and Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='green'>+0.2%</font>) for some time now. At a <a href=\"https://www.cnbc.com/2017/05/18/reuters-america-investor-jim-chanos-slams-express-scripts-and-mallinckrodt-over-high-drug-prices.html\" target=\"_blank\">conference in May</a>, he called the companies' use of third parties \"a really questionable practice\" and referred to their partnership as a \"murky alliance.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3294919\" data-linked=\"Express Scripts slips on Chanos&#39; continued bearish thesis\" data-tweet=\"$ESRX $ESRX $MNK - Express Scripts slips on Chanos&#39; continued bearish thesis https://seekingalpha.com/news/3294919-express-scripts-slips-on-chanos-continued-bearish-thesis?source=tweet\" data-url=\"https://seekingalpha.com/news/3294919-express-scripts-slips-on-chanos-continued-bearish-thesis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294918\" data-ts=\"1505235640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294918-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/EQS' title='Equus Total Return'>EQS</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/BANC' title='Banc of California, Inc.'>BANC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IRET' title='Investors Real Estate Trust'>IRET</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294918\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$RTNB $EQS $GNW - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3294918-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294918-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294920\" data-ts=\"1505235626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VWAGY\" target=\"_blank\">VWAGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294920-auto-sector-lively-frankfurt-motor-show-begins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto sector lively as Frankfurt Motor Show begins</a></h4><ul><li>European automakers are seeing some share price gains as the Frankfurt International Motor Show begins with a press event.</li><li>Volkswagen (VLKAY) and Renault (<a href='https://seekingalpha.com/symbol/RNSDF' title='Renault SA'>OTC:RNSDF</a>, <a href='https://seekingalpha.com/symbol/RNLSY' title='Renault SA ADR'>OTCPK:RNLSY</a>) are&nbsp;<font color='green'>up about 2%</font>&nbsp;in European trading, while Peugeot (<a href='https://seekingalpha.com/symbol/PEUGF' title='Peugeot S.A.'>OTCPK:PEUGF</a>) is&nbsp;<font color='green'>4% higher</font>. In the U.S., Ford (<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='green'>+1.8%</font>) and General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='green'>+1.7%</font>) are both having solid days. One of the themes coming out of Frankfurt is that automakers want to focus on margins over sales volume growth.</li><li>Some suppliers are also showing strength, led by Stoneridge (<a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+3.3%</font>), Voxx International (<a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='green'>+3.1%</font>), Lydall (<a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+1.9%</font>), Visteon (<a href='https://seekingalpha.com/symbol/VC' title='Visteon Corporation'>VC</a> <font color='green'>+1.7%</font>) and Allison Transmission (<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='green'>+2.1%</font>).</li><li>Business Insider posted <a href=\"http://www.businessinsider.com/frankfurt-motor-show-2017-new-electric-cars-preview-2017-9/#its-not-purely-electric-but-mercedes-will-debut-its-hydrogen-powered-glc-the-suv-will-come-with-an-electric-motor-with-a-30-mile-electric-range-4\" target=\"_blank\">pictures</a> of many of the EV introductions and concepts being shown off at Frankfurt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294920\" data-linked=\"Auto sector lively as Frankfurt Motor Show begins\" data-tweet=\"$VWAGY $VWAGY $RNSDF - Auto sector lively as Frankfurt Motor Show begins https://seekingalpha.com/news/3294920-auto-sector-lively-frankfurt-motor-show-begins?source=tweet\" data-url=\"https://seekingalpha.com/news/3294920-auto-sector-lively-frankfurt-motor-show-begins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294915\" data-ts=\"1505235012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294915-matinas-bio-to-seek-commercialization-partner-for-dyslipidemia-med-mat9001-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas Bio to seek commercialization partner for dyslipidemia med MAT9001; shares up 1%</a></h4><ul>     <li>Matinas BioPharma (<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+0.7%</font>) has retained life sciences advisor JSB Partners &nbsp;to <a href=\"https://seekingalpha.com/pr/16937528-matinas-biopharma-retains-jsb-partners-pursue-strategic-options-mat9001\" target=\"_blank\">identify </a>a development and commercialization partner for MAT9001, a prescription-only formulation of omega-3 fatty acids for the potential treatment of people with extremely high levels of triglycerides in their blood (&gt;500 mg/dL).</li>     <li>The company says MAT9001 is more effective than Amarin's (<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+2.5%</font>) Vascepa (icosapent ethyl) based on comparative studies, adding that it wants to formalize its efforts ahead of the data readout from Amarin's REDUCE-IT study, expected in 2018.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3288895-amarins-reduce-study-continue-planned-shares-ahead-4-percent-premarket\" target=\"_blank\">Amarin's REDUCE-IT study to continue as planned; shares ahead 4% premarket</a> (Aug. 14)</li>     <li>See important <a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294915\" data-linked=\"Matinas Bio to seek commercialization partner for dyslipidemia med MAT9001; shares up 1%\" data-tweet=\"$MTNB $MTNB $AMRN - Matinas Bio to seek commercialization partner for dyslipidemia med MAT9001; shares up 1% https://seekingalpha.com/news/3294915-matinas-bio-to-seek-commercialization-partner-for-dyslipidemia-med-mat9001-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3294915-matinas-bio-to-seek-commercialization-partner-for-dyslipidemia-med-mat9001-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294916\" data-ts=\"1505234946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294916-jd-com-hires-microsoft-veteran-to-give-lift-to-cloud-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com hires Microsoft veteran to give lift to cloud unit</a></h4><ul>   <li>JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='green'>+2.3%</font>) has <a href=\"https://www.wsj.com/articles/microsoft-china-veteran-poached-by-jd-com-in-cloud-services-coup-1505214367\" target=\"_blank\">hired away</a> a Microsoft (<a href=\"http://seekingalpha.com/symbol/MSFT\" target=\"_blank\">MSFT</a> <font color='red'>-0.3%</font>) China veteran in order to give a charge to its cloud computing efforts.</li>    <li>The e-commerce firm named Samuel Shen president of its cloud unit. Shen was previously the general manager of Microsoft's cloud and enterprise business in China.</li>    <li>JD is working to make a dent in Alibaba's leading share (about 40%) of China's cloud services market; Microsoft has about 5%, well ahead of JD's share.</li>    <li>It's a blow to Microsoft to lose a 24-year veteran. Shen had led Microsoft's China Azure unit since 2015, and had also been COO at the company's Asia-Pacific Research and Development Group.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294916\" data-linked=\"JD.com hires Microsoft veteran to give lift to cloud unit\" data-tweet=\"$JD $JD $MSFT - JD.com hires Microsoft veteran to give lift to cloud unit https://seekingalpha.com/news/3294916-jd-com-hires-microsoft-veteran-to-give-lift-to-cloud-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3294916-jd-com-hires-microsoft-veteran-to-give-lift-to-cloud-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294914\" data-ts=\"1505234880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294914-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a> <font color='green'>+55%</font>. <a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/INOV' title='Inovalon'>INOV</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/EVI' title='EnviroStar, Inc.'>EVI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-8%</font>. EBIO <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294914\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$FWP $ALDX $AEMD - Midday Gainers / Losers https://seekingalpha.com/news/3294914-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294914-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294910\" data-ts=\"1505234243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCN\" target=\"_blank\">NVCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294910-success-rate-of-neovascs-tiara-valve-over-90-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Success rate of Neovasc&#39;s Tiara valve over 90%; shares up 6%</a></h4><ul><li>Thinly traded nano cap Neovasc (<a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='green'>+6%</font>) is up on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16937500-neovasc-provides-tiara-clinical-update\" target=\"_blank\">update </a>on the clinical performance of its Tiara transcatheter heart valve.</li><li>The technical success rate of the device is 91.2% (n=31/34), with no or just a trace of paravalvular leakage. All-cause 30-day mortality is 12.1% (n=4/33). The longest surviving patient has lived with Tiara for 3.5 years.</li><li>Implantations are being performed under three parallel programs.</li><li>Tiara is a self-expanding mitral bioprosthesis designed to treat mitral valve regurgitation by replacing the diseased valve.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294910\" data-linked=\"Success rate of Neovasc&#39;s Tiara valve over 90%; shares up 6%\" data-tweet=\"$NVCN - Success rate of Neovasc&#39;s Tiara valve over 90%; shares up 6% https://seekingalpha.com/news/3294910-success-rate-of-neovascs-tiara-valve-over-90-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3294910-success-rate-of-neovascs-tiara-valve-over-90-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294911\" data-ts=\"1505233833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRK.A\" target=\"_blank\">BRK.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294911-home-capital-group-rejects-berkshire-plan-shares-jump-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home Capital Group rejects Berkshire plan; shares jump 2%</a></h4><ul><li>To review, Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a>) in June took a 38.39% stake in the struggling mortgage lender as part of a bailout package (including a C$2B loan that's since been repaid).</li><li>At a special meeting today, <a href=\"https://www.wsj.com/articles/home-capital-shareholders-reject-buffetts-expanded-stake-1505231919\" target=\"_blank\">shareholders voted not</a> to allow Berkshire to boost its stake, a signal the company's owners think things have improved enough that additional capital isn't necessary.</li><li>Shares have reopened for trade in Toronto,&nbsp;<font color='green'>popping 2%</font>. The ADRs (<a href='https://seekingalpha.com/symbol/HMCBF' title='Home Capital Group Inc.'>OTCPK:HMCBF</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3294911\" data-linked=\"Home Capital Group rejects Berkshire plan; shares jump 2%\" data-tweet=\"$BRK.A $BRK.A $BRK.B - Home Capital Group rejects Berkshire plan; shares jump 2% https://seekingalpha.com/news/3294911-home-capital-group-rejects-berkshire-plan-shares-jump-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294911-home-capital-group-rejects-berkshire-plan-shares-jump-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294908\" data-ts=\"1505233335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYN\" target=\"_blank\">SYN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294908-synthetic-bio-closes-12m-convertible-debt-deal-shares-slip-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synthetic Bio closes $12M convertible debt deal; shares slip 2%</a></h4><ul><li>Synthetic Biologics (<a href='https://seekingalpha.com/symbol/SYN' title='Synthetic Biologics, Inc.'>SYN</a> <font color='red'>-2%</font>) <a href=\"https://seekingalpha.com/pr/16937485-synthetic-biologics-announces-closing-12-million-convertible-preferred-stock-financing\" target=\"_blank\">finalizes </a>the private placement of $12M of redeemable convertible preferred stock to an affiliate of MDS Partners, L.P. The initial conversion price is $0.54 per common share.</li><li>Net proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294908\" data-linked=\"Synthetic Bio closes $12M convertible debt deal; shares slip 2%\" data-tweet=\"$SYN - Synthetic Bio closes $12M convertible debt deal; shares slip 2% https://seekingalpha.com/news/3294908-synthetic-bio-closes-12m-convertible-debt-deal-shares-slip-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294908-synthetic-bio-closes-12m-convertible-debt-deal-shares-slip-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294906\" data-ts=\"1505232988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FWP\" target=\"_blank\">FWP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294906-forward-pharma-ex-dividend-today-shares-up-57\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forward Pharma ex-dividend today, shares up 57%</a></h4><ul><li>Thinly traded nano cap Forward Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a>)&nbsp;is up&nbsp;<font color='green'>57%</font>&nbsp;on almost an 18x surge in volume. The company is ex-d today which also involves a change in the ratio of ADS/ordinary share from one to two.</li><li>Yesterday, the company paid the bulk of the $1.25B from Biogen to shareholders.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293145-forward-pharma-return-917_7m-shareholders\" target=\"_blank\">Forward Pharma to return &euro;917.7M to shareholders</a> (Sept. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294906\" data-linked=\"Forward Pharma ex-dividend today, shares up 57%\" data-tweet=\"$FWP - Forward Pharma ex-dividend today, shares up 57% https://seekingalpha.com/news/3294906-forward-pharma-ex-dividend-today-shares-up-57?source=tweet\" data-url=\"https://seekingalpha.com/news/3294906-forward-pharma-ex-dividend-today-shares-up-57\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294904\" data-ts=\"1505232045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294904-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/STLY' title='HG Holdings Inc'>STLY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira'>LMNR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BG' title='Bunge Limited'>BG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294904\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KNDI $EFOI $STLY - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3294904-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294904-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294903\" data-ts=\"1505231841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294903-capitol-forum-warns-of-ftc-extension-on-walgreens-rite-aid-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capitol Forum warns of FTC extension on Walgreens-Rite Aid deal</a></h4><ul> <li>Capitol Forum says the FTC review of Walgreens Boots Alliance's (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='green'>+1.8%</font>) deal with Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-4.2%</font>) may be extended.</li> <li>The agency is said to be still evaluating the impact on drugstore competition in some markets.</li> <li>Walgreen is looking to buy 2,186 Rite Aid stores.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294903\" data-linked=\"Capitol Forum warns of FTC extension on Walgreens-Rite Aid deal\" data-tweet=\"$WBA $WBA $RAD - Capitol Forum warns of FTC extension on Walgreens-Rite Aid deal https://seekingalpha.com/news/3294903-capitol-forum-warns-of-ftc-extension-on-walgreens-rite-aid-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3294903-capitol-forum-warns-of-ftc-extension-on-walgreens-rite-aid-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>339&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294898\" data-ts=\"1505230673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294898-caterpillar-up-nearly-2-on-investor-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar up nearly 2% on Investor Day</a></h4><ul><li>Caterpillar's (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='green'>+1.9%</font>) Investor Day presentations got underway about 30 minutes ago.</li><li><a href=\"http://www.caterpillar.com/en/investors/events-and-presentations.html\" target=\"_blank\">Webcast and presentation slides</a></li><li>As part of the financial review, CFO Brad Halverson says the company is targeting an improvement of 200-500 basis points over the current 12% operating margin.</li><li>CAT is also targeting a 30%-45% ME&amp;T debt-to-cap ratio vs. the current 40%. ME&amp;T capex going forward is seen at $1B-$1.5B per year vs. the 2012-16 average of $2.1B per year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294898\" data-linked=\"Caterpillar up nearly 2% on Investor Day\" data-tweet=\"$CAT - Caterpillar up nearly 2% on Investor Day https://seekingalpha.com/news/3294898-caterpillar-up-nearly-2-on-investor-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3294898-caterpillar-up-nearly-2-on-investor-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294895\" data-ts=\"1505229295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTH\" target=\"_blank\">HTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294895-hilltop-holdings-up-4-on-relief-over-harvey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hilltop Holdings up 4% on relief over Harvey</a></h4><ul><li><a href=\"http://www.snl.com/Cache/c390240310.html\" target=\"_blank\">Full filing</a></li><li>The company operates 20 offices in hurricane affected markets. Of those, one is not fully operational thanks to flooding. All employees have been moved to other branches and are functioning in normal capacity.</li><li>About 11% of total bank loans are in hurricane affected areas, and initial calls indicate limited damages.</li><li>As for mortgages, the bank had $40M in funded loans not yet sold into secondary markets.</li><li>Insurance coverage: Gross losses are expected to be well below the $105M coverage limit.</li><li><a href='https://seekingalpha.com/symbol/HTH' title='Hilltop Holdings Inc.'>HTH</a>&nbsp;<font color='green'>+4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3294895\" data-linked=\"Hilltop Holdings up 4% on relief over Harvey\" data-tweet=\"$HTH - Hilltop Holdings up 4% on relief over Harvey https://seekingalpha.com/news/3294895-hilltop-holdings-up-4-on-relief-over-harvey?source=tweet\" data-url=\"https://seekingalpha.com/news/3294895-hilltop-holdings-up-4-on-relief-over-harvey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294860\" data-ts=\"1505228453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294860-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a> <font color='green'>+58%</font>. <a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='green'>+54%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294860\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$FWP $ALDX $AEMD - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3294860-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3294860-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294889\" data-ts=\"1505228428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294889-biopharmxs-bpxminus-01-shows-encouraging-action-in-early-stage-rosacea-study-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX&#39;s BPX-01 shows encouraging action in early-stage rosacea study; shares ahead 5%</a></h4><ul><li>Nano cap BioPharmX (<a href='https://seekingalpha.com/symbol/BPMX' title='BioPharmX Corporation'>BPMX</a> <font color='green'>+5.4%</font>) is up on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/16937527-biopharmx-announces-preliminary-data-rosacea-feasibility-study\" target=\"_blank\">announcement </a>of positive results from a feasibility study of BPX-01, a topical minocycline gel for the treatment of rosacea. Preliminary data showed that BPX-01 was well-tolerated and suggested a positive effect on rosacea lesions. In 15 subjects who completed 12 weeks of treatment, all had IGA scores of clear or almost clear, with a 93% reduction in total inflammatory lesions from baseline.</li><li>The company intends to conduct additional research to evaluate the efficacy of BPX-01 in rosacea.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294889\" data-linked=\"BioPharmX&#39;s BPX-01 shows encouraging action in early-stage rosacea study; shares ahead 5%\" data-tweet=\"$BPMX - BioPharmX&#39;s BPX-01 shows encouraging action in early-stage rosacea study; shares ahead 5% https://seekingalpha.com/news/3294889-biopharmxs-bpxminus-01-shows-encouraging-action-in-early-stage-rosacea-study-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3294889-biopharmxs-bpxminus-01-shows-encouraging-action-in-early-stage-rosacea-study-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294891\" data-ts=\"1505228299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGS\" target=\"_blank\">PRGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294891-progress-software-updates-guidance-for-q3-sharesplus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progress Software updates guidance for Q3; Shares +3%</a></h4><ul>     <li>Progress Software (<a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a> <font color='green'>+3.5%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/16937553-progress-software-announces-preliminary-financial-results-fiscal-q3-2017-better-expected-q3\" target=\"_blank\">now expects</a>&nbsp;Non-GAAP revenue in Q3 to be ~$97.6M vs. a consensus of $96.03M and prior guidance range of $93.0M - $96.0M.</li>     <li>Non-GAAP EPS expected to be ~$0.48 vs. a consensus of $0.43 and prior guidance of $0.41 - $0.43.</li>     <li>Progress also <a href=\"https://seekingalpha.com/news/3294807-progress-software-declares-0_14-dividend\" target=\"_blank\">announced</a> that its Board of Directors approved a&nbsp;<font color='green'>12%</font>&nbsp;<font color='green'>increase&nbsp;</font>in the Company&rsquo;s quarterly cash dividend.</li>     <li>Progress Software will report Q3 on Sept. 27, after the close of market.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3294891\" data-linked=\"Progress Software updates guidance for Q3; Shares +3%\" data-tweet=\"$PRGS - Progress Software updates guidance for Q3; Shares +3% https://seekingalpha.com/news/3294891-progress-software-updates-guidance-for-q3-sharesplus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3294891-progress-software-updates-guidance-for-q3-sharesplus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294888\" data-ts=\"1505228054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294888-gap-rallies-after-jefferies-value-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gap rallies after Jefferies value call</a></h4><ul> <li>Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) breaks higher after Jefferies tabulates that the company's Old Navy business is worth 30% more than the total enterprise value of the retailer.</li> <li>Analyst Randal Konik observes that Old Navy generates 75% of Gap's profit. He also points to the potential for stronger free cash flow across the company as management resets priorities.</li> <li>Konik sets a price target of $39 on Buy-rated Gap to rep 44% upside and calls it a top pick.</li><li>Gap is&nbsp;<font color='green'>up 5.44%</font>&nbsp;on the day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294888\" data-linked=\"Gap rallies after Jefferies value call\" data-tweet=\"$GPS - Gap rallies after Jefferies value call https://seekingalpha.com/news/3294888-gap-rallies-after-jefferies-value-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3294888-gap-rallies-after-jefferies-value-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294884\" data-ts=\"1505227747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMPH\" target=\"_blank\">KMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294884-kempharm-completes-dispute-resolution-process-fda-over-apadaz-application-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KemPharm completes dispute resolution process with FDA over Apadaz application; shares up 2%</a></h4><ul><li>Thinly traded nano cap KemPharm (<a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a>) perks up&nbsp;<font color='green'>2%</font>&nbsp;on modestly higher volume after it <a href=\"https://seekingalpha.com/pr/16937517-kempharm-announces-fdrr-process-completion-resubmission-apadaz-nda\" target=\"_blank\">announced </a>that it has completed the Formal Dispute Resolution Request &#40;FDRR&#41; process with the FDA related to its New Drug Application &#40;NDA&#41; for Apadaz (benzhydrocodone and acetaminophen). The company received a CRL on June 13, 2016.</li><li>The agency has notified that its NDA is complete. Its action date is February 23, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3180749-ad-comm-backs-approval-kempharms-pain-med-apadaz-abuse-deterrent-claim-shares-plummet-45\" target=\"_blank\">Ad Comm backs approval of KemPharm's pain med Apadaz but not abuse-deterrent claim; shares plummet 45% premarket</a> (May 6, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294884\" data-linked=\"KemPharm completes dispute resolution process with FDA over Apadaz application; shares up 2%\" data-tweet=\"$KMPH - KemPharm completes dispute resolution process with FDA over Apadaz application; shares up 2% https://seekingalpha.com/news/3294884-kempharm-completes-dispute-resolution-process-fda-over-apadaz-application-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294884-kempharm-completes-dispute-resolution-process-fda-over-apadaz-application-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294879\" data-ts=\"1505227016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294879-mabvax-secures-2m-private-capital-raise-shares-down-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax secures $2M private capital raise; shares down 18%</a></h4><ul><li>MabVax Therapeutics Holdings (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a> <font color='red'>-18.2%</font>) inks an <a href=\"https://seekingalpha.com/pr/16937749-mabvax-therapeutics-holdings-inc-announces-2_0-million-registered-direct-offering\" target=\"_blank\">agreement </a>with investors to sell 4M shares of common stock at $0.50 per share. Net proceeds of ~$1.9M will fund the continued development of MVT-5873 in pancreatic cancer.</li><li>Yesterday's close was $0.66.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294879\" data-linked=\"MabVax secures $2M private capital raise; shares down 18%\" data-tweet=\"$MBVX $MBVXQ - MabVax secures $2M private capital raise; shares down 18% https://seekingalpha.com/news/3294879-mabvax-secures-2m-private-capital-raise-shares-down-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3294879-mabvax-secures-2m-private-capital-raise-shares-down-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294875\" data-ts=\"1505226588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294875-galectin-nabs-patent-in-china-covering-lead-candidate-gr-mdminus-02-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin nabs patent in China covering lead candidate GR-MD-02; shares ahead 4%</a></h4><ul><li>Thinly traded micro cap Galectin Therapeutics (<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+3.5%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16937798-galectin-therapeutics-receives-notice-chinese-allowance-grant-key-patent-composition-matter\" target=\"_blank\">announcement </a>that the Chinese Patent Office has approved its application for a composition of matter patent covering lead candidate GR-MD-02. &nbsp;The patent will be in effect through 2032.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294875\" data-linked=\"Galectin nabs patent in China covering lead candidate GR-MD-02; shares ahead 4%\" data-tweet=\"$GALT - Galectin nabs patent in China covering lead candidate GR-MD-02; shares ahead 4% https://seekingalpha.com/news/3294875-galectin-nabs-patent-in-china-covering-lead-candidate-gr-mdminus-02-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3294875-galectin-nabs-patent-in-china-covering-lead-candidate-gr-mdminus-02-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294876\" data-ts=\"1505226397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294876-mcdonalds-sales-seen-tracking-below-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDonald&#39;s sales seen tracking below consensus</a></h4><ul> <li>The hit to McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>) today is based off of M Science CEO Michael Marrale's update that \"we are below\" consensus estimates on U.S. comparable sales.</li> <li>M Science catches a lot of attention in the restaurant sector due to its heavy focus on data tracking in its research reports.</li> <li>Source: Bloomberg</li> <li>Shares of McDonald's are <font color='red'>2.80% lower</font>&nbsp;after being down as much as 3.4%. The stock is the worst performer on the day of the 48 publicly-traded restaurant stocks with a market cap higher than $50M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294863-mcdonalds-opens-sharply-lower\" target=\"_blank\">McDonald's opens sharply lower</a> (Sept. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294876\" data-linked=\"McDonald&#39;s sales seen tracking below consensus\" data-tweet=\"$MCD - McDonald&#39;s sales seen tracking below consensus https://seekingalpha.com/news/3294876-mcdonalds-sales-seen-tracking-below-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3294876-mcdonalds-sales-seen-tracking-below-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294871\" data-ts=\"1505225939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTNT\" target=\"_blank\">QTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294871-quotient-advancing-mosiaq-diagnostic-platform-shares-ahead-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quotient advancing MosiaQ diagnostic platform; shares ahead 32%</a></h4><ul><li>Thinly traded micro cap Quotient Limited (<a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+32.1%</font>) is up in early trading on increased volume in response to <a href=\"https://seekingalpha.com/pr/16937652-quotient-limited-reports-results-latest-mosaiq-performance-evaluation-studies-prior\" target=\"_blank\">positive data</a> from in-house studies of MosaiQ to assess its performance prior to starting verification and validation work.</li><li>The data showed MosiaQ IH Microarray (blood grouping) and MosiaQ SDS Microarray (disease screening) achieved the targeted performance compared to reference technologies. Specifically, MosiaQ IH achieved 99.1% concordance with the predicate technology while MosiaQ SDS achieved 100% sensitivity and 98% specificity for CMV and 100% sensitivity and 100% specificity for syphilis.</li><li>Key milestones:</li><li>European trials should wind up this year with regulatory filings to promptly follow.</li><li>U.S. studies and regulatory applications will follow the completion of the European studies.</li><li>MosiaQ is a next-generation platform designed for rapid comprehensive blood antigen typing, antibody detection and disease screening in a high throughput automated format.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294871\" data-linked=\"Quotient advancing MosiaQ diagnostic platform; shares ahead 32%\" data-tweet=\"$QTNT - Quotient advancing MosiaQ diagnostic platform; shares ahead 32% https://seekingalpha.com/news/3294871-quotient-advancing-mosiaq-diagnostic-platform-shares-ahead-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3294871-quotient-advancing-mosiaq-diagnostic-platform-shares-ahead-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294872\" data-ts=\"1505225387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPX\" target=\"_blank\">WPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294872-wpx-energy-up-nearly-3-after-cooperman-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WPX Energy up nearly 3% after Cooperman mention</a></h4><ul><li>Holding court at the Delivering Alpha conference, <a href=\"http://www.deliveringalpha.com/2017/09/12/here-are-billionaire-leon-coopermans-5-favorite-cheap-stocks-right-now.html\" target=\"_blank\">Leon Cooperman mentions</a> WPX Energy (<a href='https://seekingalpha.com/symbol/WPX' title='WPX Energy, Inc.'>WPX</a> <font color='green'>+2.9%</font>) as one of his picks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294872\" data-linked=\"WPX Energy up nearly 3% after Cooperman mention\" data-tweet=\"$WPX - WPX Energy up nearly 3% after Cooperman mention https://seekingalpha.com/news/3294872-wpx-energy-up-nearly-3-after-cooperman-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3294872-wpx-energy-up-nearly-3-after-cooperman-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294869\" data-ts=\"1505225123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294869-goldman-leads-tbtfs-higher-after-conference-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman leads TBTFs higher after conference presentation</a></h4><ul><li>The bank lays out its case for how it can achieve an additional $5B in revenue over the next three years.</li><li>Of that $5B, $2B is seen coming from actual lending. Goldman's (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='green'>+1.9%</font>) retail lending platform (named Marcus) recently crossed $1B in loan originations, and expects to hit $2B by the end of the year. Deposits have topped $15B.</li><li>Goldman also sees an opportunity to boost the&nbsp;beleaguered FICC business by $1B over three years. Among the necessary steps: Deepening penetration with asset managers and banks (FICC sales fell 15% Y/Y in H1 with asset mangers, and 17% with banks/brokers).</li><li>Goldman ranks in top three in FICC with just 30% of asset managers and 29% of banks. This compares to 56% of hedge funds and 36% of insurance companies. \"There are market share gaps to close,\" says Goldman.</li><li><a href=\"http://www.goldmansachs.com/investor-relations/presentations/2017-barclays-conference-presentation.pdf\" target=\"_blank\">Presentation slides</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294869\" data-linked=\"Goldman leads TBTFs higher after conference presentation\" data-tweet=\"$GS - Goldman leads TBTFs higher after conference presentation https://seekingalpha.com/news/3294869-goldman-leads-tbtfs-higher-after-conference-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3294869-goldman-leads-tbtfs-higher-after-conference-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294865\" data-ts=\"1505224686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294865-fda-accepts-tevas-marketing-application-for-expanded-use-of-trisenox-under-priority-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Teva&#39;s marketing application for expanded use of Trisenox under Priority Review</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16937633-teva-receives-fda-priority-review-first-line-use-trisenox-arsenic-trioxide-patients-low\" target=\"_blank\">accepts under Priority Review</a> Teva Pharmaceutical Industries' (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+5.5%</font>) supplemental New Drug Application seeking approval to use TRISENOX (arsenic trioxide), in combination with retinoic acid, for induction of remission and consolidation in patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukemia &#40;APL&#41;&nbsp;characterized by a particular genetic profile [t(15;17) translocation].</li><li>TRISENOX is currently approved for induction of remission and consolidation in patients with acute APL who are refractory to or relapsed from retinoid and anthracycline chemo and whose APL has the same genetic profile cited above.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294865\" data-linked=\"FDA accepts Teva&#39;s marketing application for expanded use of Trisenox under Priority Review\" data-tweet=\"$TEVA - FDA accepts Teva&#39;s marketing application for expanded use of Trisenox under Priority Review https://seekingalpha.com/news/3294865-fda-accepts-tevas-marketing-application-for-expanded-use-of-trisenox-under-priority-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3294865-fda-accepts-tevas-marketing-application-for-expanded-use-of-trisenox-under-priority-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294863\" data-ts=\"1505224047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294863-mcdonalds-opens-sharply-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDonald&#39;s opens sharply lower</a></h4><ul> <li>McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>) is <font color='red'>down 2.84%</font> in opening trades without any major news announcement out from the company.</li> <li>There is some indication that a negtive note from M Science on comparable sales may be playing a factor.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294863\" data-linked=\"McDonald&#39;s opens sharply lower\" data-tweet=\"$MCD - McDonald&#39;s opens sharply lower https://seekingalpha.com/news/3294863-mcdonalds-opens-sharply-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3294863-mcdonalds-opens-sharply-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294861\" data-ts=\"1505223816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294861-fda-accepts-arrays-marketing-application-for-combo450-action-date-june-30-2018-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Array&#39;s marketing application for COMBO450; action date June 30, 2018; shares up 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16938097-array-biopharma-announces-fda-acceptance-review-binimetinib-encorafenib-new-drug-applications\" target=\"_blank\">accepts for review </a>Array BioPharma's (<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+1.5%</font>) New Drug Applications (NDAs) seeking approval for the combination of binimetinib (45 mg twice daily) and encorafenib (450 mg once daily) (COMBO450) for the treatment of BRAF-positive advanced, unresectable/metastatic melanoma.</li><li>The agency's action date &#40;PDUFA&#41;&nbsp;is June 30, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294861\" data-linked=\"FDA accepts Array&#39;s marketing application for COMBO450; action date June 30, 2018; shares up 2%\" data-tweet=\"$ARRY - FDA accepts Array&#39;s marketing application for COMBO450; action date June 30, 2018; shares up 2% https://seekingalpha.com/news/3294861-fda-accepts-arrays-marketing-application-for-combo450-action-date-june-30-2018-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294861-fda-accepts-arrays-marketing-application-for-combo450-action-date-june-30-2018-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294849\" data-ts=\"1505222446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294849-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='green'>+53%</font>&nbsp;on its lead product candidate <a href=\"https://seekingalpha.com/news/3294824-aldeyras-lead-product-candidate-successful-mid-stage-dry-eye-study-shares-ahead-38-percent\" target=\"_blank\">successful</a> in mid-stage dry eye study.</li>     <li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+47%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3294819-fda-designates-aethlon-hemopurifier-accelerated-review-shares-ahead-35-percent-premarket\" target=\"_blank\">designates</a> Aethlon' Hemopurifier for accelerated review.</li>     <li><a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294809-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a> <font color='green'>+7%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/16937212-travelcenters-america-llc-wins-litigation-comdata\" target=\"_blank\">announcement</a> that it has won its litigation against Comdata.</li>     <li><a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294738-teva-sells-paragard-asset-coopersurgical-1_1b\" target=\"_blank\">selling</a> Paragard asset to CooperSurgical for $1.1B.</li>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16937895-dryships-inc-announces-commencement-second-large-gas-carrier-5-year-time-charter-oil-major\" target=\"_blank\">commencement</a> of Its second very large gas carrier 5 year time charter with an oil major.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294849\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$ALDX $AEMD $CTIC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3294849-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294849-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294848\" data-ts=\"1505222380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294848-lake-street-says-bearish-sa-article-rehash-of-old-news-recommends-aggressive-buying-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lake Street says bearish SA article a &quot;rehash&quot; of old news, recommends aggressive buying; investors appear to disagree, shares down 15% premarket</a></h4><ul><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>) is poised to continue yesterday's slide, down&nbsp;<font color='red'>15%</font>&nbsp;premarket on robust volume, despite management's conference call yesterday aimed at stemming the selloff after SA Contributor Richard Pearson published a bearish report on the company.</li><li>Bullish sell-sider Lake Street believes investors overreacted since Mr. Pearson's article is mostly \"rehashing old benign regulatory items that have little or no materiality.\" It says it would be an \"aggressive buyer\" of the stock as investors realize their mistake. Lake maintains its $37 (58% upside) price target.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294627-health-insurance-innovations-pressure-bearish-report-sa-contributor-pearson-shares-14-percent\" target=\"_blank\">Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14%</a> (Sept. 11)</li><li><strong>Update</strong>: In a <a href=\"https://seekingalpha.com/pr/16938086-health-insurance-innovations-inc-addresses-misleading-information-marketplace\" target=\"_blank\">statement</a>, the company says the Indiana Multi-State examination remains open and the alleged $100M potential fine is not based on any facts.</li><li>The Florida licensure issue in ongoing. A final hearing was scheduled for October 17-20 but was postponed. The company is in talks with the Office of Insurance Regulation on a potential resolution.</li><li>There are no \"undisclosed legal actions\" against company insiders. There were two cases involving CFO Michael Hershberger when he was a real estate developer in Wisconsin, one which was quickly settled and the other where he was mistakenly named as a party (subsequently dismissed).</li></ul><div class=\"tiny-share-widget\" data-id=\"3294848\" data-linked=\"Lake Street says bearish SA article a &quot;rehash&quot; of old news, recommends aggressive buying; investors appear to disagree, shares down 15% premarket\" data-tweet=\"$HIIQ - Lake Street says bearish SA article a &quot;rehash&quot; of old news, recommends aggressive buying; investors appear to disagree, shares down 15% premarket https://seekingalpha.com/news/3294848-lake-street-says-bearish-sa-article-rehash-of-old-news-recommends-aggressive-buying-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3294848-lake-street-says-bearish-sa-article-rehash-of-old-news-recommends-aggressive-buying-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294844\" data-ts=\"1505222222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294844-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>&nbsp;<font color='red'>-24%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294803-sage-therapeutics-lead-product-candidate-flunks-late-stage-srse-study-shares-25-percent\" target=\"_blank\">reporting</a> top-line results from Phase 3 STATUS trial of Brexanolone in super-refractory status epilepticus.</li><li><a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294830-intercept-pressure-ocaliva-associated-liver-injury-dosed-frequently-recommended-shares-14\" target=\"_blank\">Ocaliva-associated liver injury</a> when dosed more frequently that recommended.</li><li><a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>&nbsp;<font color='red'>-16%</font>&nbsp;on bearish <a href=\"https://seekingalpha.com/news/3294710-health-insurance-innovations-host-investor-call-today-4-30-pm-et\" target=\"_blank\">report</a> from SA contributor Pearson.</li><li><a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294719-biocryst-pharma-deck-80m-equity-offering\" target=\"_blank\">commencing</a> public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/BIP' title='Brookfield Infrastructure Partners L.P.'>BIP</a> <font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16937068-brookfield-infrastructure-announces-1-billion-equity-offering\" target=\"_blank\">announcing</a> $1B equity offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294844\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$SAGE $ICPT $HIIQ - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3294844-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294844-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294839\" data-ts=\"1505221626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294839-alexion-confirms-move-to-boston-20-cut-in-workforce-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion confirms move to Boston, 20% cut in workforce; shares up 2% premarket</a></h4><ul><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) <a href=\"https://seekingalpha.com/pr/16937615-alexion-announces-restructuring-advance-corporate-strategy\" target=\"_blank\">plans to realign</a> and refocus its organization aimed at lowering operating costs and boosting productivity. The company says the initiative, which includes a 20% downsizing in headcount, should save $270M in annual operating expenses by 2019.</li><li>It intends to reinvest ~$100M per year in R&amp;D.</li><li>Corporate headquarters will be moved to Boston by mid-2018 while its 450-employee Research Center of Excellence will be based in New Haven, CT.</li><li>Management expects to record pretax charges of $340M - 440M related to the plan, half of which will be cash outlays.</li><li>2017 revenue and non-GAAP EPS guidance remain as is. GAAP EPS guidance will be negatively impacted.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294839\" data-linked=\"Alexion confirms move to Boston, 20% cut in workforce; shares up 2% premarket\" data-tweet=\"$ALXN - Alexion confirms move to Boston, 20% cut in workforce; shares up 2% premarket https://seekingalpha.com/news/3294839-alexion-confirms-move-to-boston-20-cut-in-workforce-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3294839-alexion-confirms-move-to-boston-20-cut-in-workforce-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294830\" data-ts=\"1505220655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294830-intercept-under-pressure-on-ocaliva-associated-liver-injury-when-dosed-frequently-recommended\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept under pressure on Ocaliva-associated liver injury when dosed more frequently that recommended; shares down 14% premarket</a></h4><ul><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) slumps&nbsp;<font color='red'>14%</font>&nbsp;premarket on increased volume, poised to continue the slide that accelerated yesterday with shares down&nbsp;<font color='red'>3%</font>. The culprit appears to be a September 8 <a href=\"https://ocalivahcp.com/_assets/_pdfs/Ocaliva-Dear-HCP-Letter-9.8.17.pdf\" target=\"_blank\">announcement </a>from the company that severe adverse events, including liver failure and death, can occur if physicians fail to follow the recommended dosing regimen for OCALIVA (obeticholic acid) in patients with primary biliary cholangitis &#40;PBC&#41;.</li><li>The note, from Chief Medical Officer David Shapiro, M.D., reviewed the FDA-approved dosing scheme and recommended patient monitoring approach, adding that healthcare providers should \"exercise a low threshold for drug discontinuation or interruption based on [ ] evidence of toxicities.\"</li><li>In July, the company reported a death in its mid-stage NASH study of obeticholic acid.</li><li>NASH competitor Genfit (<a href='https://seekingalpha.com/symbol/GNFTF' title='Genfit'>OTCPK:GNFTF</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;in European trading.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283400-intercepts-q2-beat-overcome-pressure-reported-death-mid-stage-nash-study-shares-8-percent\" target=\"_blank\">Intercept's Q2 beat can't overcome pressure from reported death in mid-stage NASH study; shares down 8%</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294830\" data-linked=\"Intercept under pressure on Ocaliva-associated liver injury when dosed more frequently that recommended; shares down 14% premarket\" data-tweet=\"$ICPT $ICPT $GNFTF - Intercept under pressure on Ocaliva-associated liver injury when dosed more frequently that recommended; shares down 14% premarket https://seekingalpha.com/news/3294830-intercept-under-pressure-on-ocaliva-associated-liver-injury-when-dosed-frequently-recommended?source=tweet\" data-url=\"https://seekingalpha.com/news/3294830-intercept-under-pressure-on-ocaliva-associated-liver-injury-when-dosed-frequently-recommended\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294828\" data-ts=\"1505219637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DWDP\" target=\"_blank\">DWDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294828-dowdupont-to-realign-businesses-after-review-shares-up-2_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DowDupont to realign businesses after review; shares up 2.6%</a></h4><ul><li>The businesses that will be realigned to the Specialty Products Division account for total net sales of more than $8B, and operating EBTIDA of $2.4B, including about 40% of the heritage Dow Corning EBITDA.</li><li>Reiterated are plans to achieve cost synergies of about $3B, and growth synergies of roughly $1B.</li><li>A <a href=\"http://edge.media-server.com/m/p/i9vsepr5\" target=\"_blank\">conference call</a> is just getting underway.</li><li><a href='https://seekingalpha.com/symbol/DWDP' title='DowDuPont Inc.'>DWDP</a>&nbsp;<font color='green'>+2.6%</font>&nbsp;premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/16937376-dowdupont-announces-results-comprehensive-portfolio-review\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294828\" data-linked=\"DowDupont to realign businesses after review; shares up 2.6%\" data-tweet=\"$DWDP $DD - DowDupont to realign businesses after review; shares up 2.6% https://seekingalpha.com/news/3294828-dowdupont-to-realign-businesses-after-review-shares-up-2_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3294828-dowdupont-to-realign-businesses-after-review-shares-up-2_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294824\" data-ts=\"1505219210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294824-aldeyras-lead-product-candidate-successful-in-mid-stage-dry-eye-study-shares-ahead-38\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra&#39;s lead product candidate successful in mid-stage dry eye study; shares ahead 38% premarket</a></h4><ul><li>Thinly traded nano cap Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) is up&nbsp;<font color='green'>38%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16937482-aldeyra-therapeutics-announces-positive-results-dry-eye-disease-phase-2a-clinical-trial\" target=\"_blank\">announcement </a>of positive results from a Phase 2a clinical trial assessing lead product candidate ADX-102 in patients with dry eye disease.</li><li>Results from pooled data over a 28-day treatment period showed a statistically significant improvement from baseline a range of measures related to dry eye symptoms. The company says the improvements were evident within one week of treatment.</li><li>The primary objective of the Phase 2a was the selection of a formulation, 0.1% ADX-102, and dose range for a Phase 2b study.</li><li>No safety signals were observed.</li><li><a href=\"http://www.aldeyra.com/for-physicians/\" target=\"_blank\">ADX-102</a>&nbsp;is an aldehyde-binding molecule or aldehyde trap. By decreasing aldehyde load, it may mitigate excessive inflammation caused by excess aldehydes. It was unsuccessful in a mid-stage conjunctivitis study reported in June.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273373-aldeyras-lead-product-candidate-flunks-mid-stage-allergic-conjunctivitis-study-shares-19\" target=\"_blank\">Aldeyra's lead product candidate flunks mid-stage allergic conjunctivitis study; shares down 19% premarket</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294824\" data-linked=\"Aldeyra&#39;s lead product candidate successful in mid-stage dry eye study; shares ahead 38% premarket\" data-tweet=\"$ALDX - Aldeyra&#39;s lead product candidate successful in mid-stage dry eye study; shares ahead 38% premarket https://seekingalpha.com/news/3294824-aldeyras-lead-product-candidate-successful-in-mid-stage-dry-eye-study-shares-ahead-38?source=tweet\" data-url=\"https://seekingalpha.com/news/3294824-aldeyras-lead-product-candidate-successful-in-mid-stage-dry-eye-study-shares-ahead-38\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294823\" data-ts=\"1505219150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSBF\" target=\"_blank\">TOSBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294823-reuters-toshiba-still-considering-chip-unit-bidders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Toshiba still considering chip unit bidders</a></h4><ul><li>        <a href=\"http://www.reuters.com/article/us-toshiba-accounting/toshiba-still-in-talks-over-chip-unit-sale-one-day-before-deadline-sources-idUSKCN1BM2T6\" target=\"_blank\">Reuters</a> reports that Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) denies yesterday&rsquo;s rumor that the company had selected Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) as the winning bidder for its chip unit. Toshiba says no decision has been made yet.</li><li>               Toshiba has missed a few self-imposed deadlines to select a bidder and now has tomorrow as its new deadline.&nbsp;</li><li>               A consortium containing Western Digital remains a top bidder but Toshiba and Apple have reportedly expressed concerns about the company possibly taking control of the chip unit rather than remaining an investor.&nbsp;</li><li>               Other bidders include a consortium led by Bain Capital and Toshiba competitor SK Hynix and one led by Apple supplier Foxconn.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='green'>up 2.03%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294751-report-western-digital-wins-bid-toshiba-chip-unit\" target=\"_blank\">Report: Western Digital wins bid for Toshiba chip unit</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294823\" data-linked=\"Reuters: Toshiba still considering chip unit bidders\" data-tweet=\"$TOSBF $TOSBF $TOSYY - Reuters: Toshiba still considering chip unit bidders https://seekingalpha.com/news/3294823-reuters-toshiba-still-considering-chip-unit-bidders?source=tweet\" data-url=\"https://seekingalpha.com/news/3294823-reuters-toshiba-still-considering-chip-unit-bidders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294819\" data-ts=\"1505218444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEMD\" target=\"_blank\">AEMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294819-fda-designates-aethlons-hemopurifier-for-accelerated-review-shares-ahead-35-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA designates Aethlon&#39;s Hemopurifier for accelerated review; shares ahead 35% premarket</a></h4><ul>\n<li>Thinly traded nano cap Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) is up<font color=\"green\">35%</font>premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16937534-aethlon-medical-receives-expedited-access-pathway-designation-fda-accelerate-u-s-access\" target=\"_blank\">announcement </a>that the FDA has granted Expedited Access Pathway &#40;EAP&#41; status for its Hemopurifier to treat life-threatening viruses.</li>\n<li>The FDA established the EAP program in order to reduce the time to market for devices that have the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases while maintaining its PMA approval standards.</li>\n<li>The<a href=\"http://www.aethlonmedical.com/products/ellsa-exosome-assay.htm\" target=\"_blank\">Hemopurifier</a>is a biofiltration device that targets the broad-spectrum elimination of viruses, bacterial toxins and immunosuppressive proteins from the blood.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/2200865-fda-clears-aethlons-hemopurifier-ide-supplement-to-include-ebola\" target=\"_blank\">FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola</a> (Dec. 31, 2014)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3294819\" data-linked=\"FDA designates Aethlon&#39;s Hemopurifier for accelerated review; shares ahead 35% premarket\" data-tweet=\"$AEMD - FDA designates Aethlon&#39;s Hemopurifier for accelerated review; shares ahead 35% premarket https://seekingalpha.com/news/3294819-fda-designates-aethlons-hemopurifier-for-accelerated-review-shares-ahead-35-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3294819-fda-designates-aethlons-hemopurifier-for-accelerated-review-shares-ahead-35-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294809\" data-ts=\"1505217132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294809-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) initiated with Buy rating and $7.50 (131% upside) price target by Jefferies. Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket.</li><li>LivaNova (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVN' title='LivaNova PLC'>LIVN</a>) initiated with Overweight rating and $75 (14% upside) price target by Piper Jaffray.</li><li>Inovalon Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/INOV' title='Inovalon'>INOV</a>) upgraded to Equal Weight with a $14 (4% downside risk) price target by Morgan Stanley.</li><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) price target raised to $30 (14% upside) from $28 by Needham citing upside on Cabometyx in kidney cancer. Shares are up a fraction premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294809\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$CTIC $CTIC $LIVN - Premarket analyst action - healthcare https://seekingalpha.com/news/3294809-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3294809-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294803\" data-ts=\"1505216363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294803-sage-therapeutics-lead-product-candidate-flunks-late-stage-srse-study-shares-down-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics&#39; lead product candidate flunks late-stage SRSE study; shares down 25% premarket</a></h4><ul><li>Thinly traded Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) slumps&nbsp;<font color='red'>25%</font>&nbsp;premarket on increased volume in response to is <a href=\"https://seekingalpha.com/pr/16937363-sage-therapeutics-reports-top-line-results-phase-3-status-trial-brexanolone-super-refractory\" target=\"_blank\">announcement </a>that a Phase 3 clinical trial, STATUS, assessing lead product candidate SAGE-547 (brexanolone) in patients with super-refractory status epilepticus &#40;SRSE&#41; failed to achieve its primary endpoint. Specifically, brexanolone did not perform much better than placebo in successfully weaning SRSE patients off third-line agents and resolving SRSE (43.9% vs. 42.4%; p=0.8775).</li><li>The secondary endpoints were also missed.</li><li>Complete results will be submitted for presentation at a future medical conference.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294803\" data-linked=\"Sage Therapeutics&#39; lead product candidate flunks late-stage SRSE study; shares down 25% premarket\" data-tweet=\"$SAGE - Sage Therapeutics&#39; lead product candidate flunks late-stage SRSE study; shares down 25% premarket https://seekingalpha.com/news/3294803-sage-therapeutics-lead-product-candidate-flunks-late-stage-srse-study-shares-down-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3294803-sage-therapeutics-lead-product-candidate-flunks-late-stage-srse-study-shares-down-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":58,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}